EPI 12322

Drug Profile

EPI 12322

Latest Information Update: 09 Jul 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator EpiGenesis Pharmaceuticals
  • Class Antiasthmatics
  • Mechanism of Action Adenosine deaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 09 Jul 2013 Discontinued - Preclinical for Asthma in USA (unspecified route)
  • 30 Aug 2002 No development reported - Preclinical for Asthma in USA (unspecified route)
  • 27 Jul 1999 Preclinical development for Asthma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top